NMC
ABVX

Nine Masts Capital’s Abivax ABVX Stock Holding History

Nine Masts Capital’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133K Sell
998
-6,502
-87% -$736K 0.01% 151
2026
Q1 		$835K Buy
7,500
+3,500
+88% +$414K 0.12% 62
2025
Q4 		$539K Buy
+4,000
New +$436K 0.09% 60

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nine Masts Capital's ABVX Position: Q2 2026 in Review

Nine Masts Capital reduced its Abivax (ABVX) stake by 87% in Q2 2026, selling an estimated $736K and leaving 998 shares worth $133K. The position accounts for 0.01% of the portfolio, ranked #151.

Nine Masts Capital first reported a position in ABVX in Q4 2025 and has held it in 3 quarters since. The position peaked at $835K in Q1 2026. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Nine Masts Capital held 998 shares of Abivax worth $133K as of Q2 2026.
  • Nine Masts Capital sold 6,502 Abivax shares in Q2 2026, an estimated $736K.
  • Abivax made up 0.01% of Nine Masts Capital's portfolio in Q2 2026, its #151 holding.
  • Nine Masts Capital first reported a position in Abivax in Q4 2025 and has held it in 3 quarters since.
  • Nine Masts Capital's Abivax position peaked at $835K in Q1 2026.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.